• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Poland·Healthcare·SNT.WA
Share

Synektik Spólka Akcyjna Stocks

PLN 337Last Updated 09.09.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

PLN 761.64M

PLN 337
Key Takeaways

Risk factor

Limited default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Synektik Spólka Akcyjna, founded in 2001 and headquartered in Warsaw, Poland, operates as a comprehensive provider of products, services, and information technology solutions within the Polish market. The company focuses its offerings on the fields of surgery, diagnostic imaging, and nuclear medicine. Its core business activities include the distribution of medical equipment utilized in diagnostics, therapy, and nuclear medicine, alongside the creation of specialized IT solutions for radiology. Synektik also manufactures and supplies radiopharmaceutical products crucial for cancer diagnostics. In addition to these, it maintains a research laboratory dedicated to advancing diagnostic imaging systems and runs a service center for medical apparatus. The company further extends its services to include maintenance for medical equipment and the execution of essential acceptance and specialist tests.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasona

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of SNT.WA is 360 and suggests 6.74% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.09.2026 00:58

Data from some Revolut customers was leaked

12.09.2026 16:01

Small caps last week: Chewy's earnings miss, Signet's best day ever, AE rethinks ads

12.09.2026 13:01

The iPhone Reboot, the AGI Era, and Silicon Valley's Right Turn

12.09.2026 05:06

Spam from OpenAI's AI agents disrupted the developer service for four days

12.09.2026 03:52

Citrini, the founder who spooked the market with his prediction of AI threats, has sold the company. What's next?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026